What Has Been the Progress and Growth of the HIV Drugs Market in Recent Years?
The hiv drugs market has seen considerable growth due to a variety of factors.
• The market size for HIV drugs has been expanding consistently over recent years. The market is projected to increase from $34.91 billion in 2024 to $36.41 billion in 2025, at a compound annual growth rate (CAGR) of 4.3%.
The robust growth during the historical spell is a result of heightened government backing and initiatives, amplified spending on healthcare, increased resources allocated for HIV research and development, a spike in HIV infection cases, enhanced awareness, and economic growth in developing markets.
What Does the Future Hold for the HIV Drugs Market?
The hiv drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market for HIV drugs is anticipated to display consistent expansion over the upcoming years, with its valuation expected to hit $42.34 billion by 2029, growing at a compound annual growth rate (CAGR) of 3.8%.
Factors contributing to this growth during the forecasted period include enhanced government backing and initiatives, a surge in healthcare spending, expanded investment in HIV research and development, a heightened prevalence of HIV, increased awareness, and economic growth in rapidly evolving markets. Key trends projected for this period encompass investment in 3D bioprinting technology, the introduction of new product innovations, the development of multi-class combination products for HIV treatment, and strategic alliances and partnerships.
Which Drivers Are Accelerating Growth In The HIV Drugs Market?
The rise in knowledge about HIV diagnosis and treatment is a significant factor propelling the progress of the HIV drug market. HIV/AIDS, being among the most long-term illnesses, has triggered extensive consciousness about it due to its widespread prevalence across the globe. For instance, the United Nations children's fund, UNICEF, a humanitarian aid organization in the US, shared in July 2024 that an estimated 40.0 million people globally were living with HIV in 2023. Of these, 2.38 million were children between 0-19 years. Around 685 children contracted HIV daily in 2023, and approximately 250 children died due to AIDS. This heightened awareness regarding HIV diagnosis and treatment, therefore, significantly propels the HIV drug market's growth.
What Are The Primary Segments In The Global HIV Drugs Market?
The HIV drugs market covered in this report is segmented –
1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types
2) By Administration: Oral, Parenteral
3) By Application: Hospital Pharmacies, Retail Pharmacies, Other Applications
Subsegments:
1) By Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Zidovudine (AZT), Lamivudine (3TC), Abacavir (ABC), Tenofovir disoproxil fumarate (TDF), Other NRTIs
2) By Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Efavirenz (EFV), Nevirapine (NVP), Etravirine (ETR), Rilpivirine (RPV), Other NNRTIs
3) By Protease Inhibitors (PIs): Ritonavir (RTV), Lopinavir (LPV), Darunavir (DRV), Atazanavir (ATV), Other PIs
4) By Integrase Strand Transfer Inhibitors (INSTIs): Raltegravir (RAL), Dolutegravir (DTG), Bictegravir (BIC), Other INSTIs
5) By Other Types: Entry Inhibitors, Fusion Inhibitors, Combination Therapies
Pre-Book The HIV Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The HIV Drugs Market?
Key players in the HIV drugs market are entering into strategic partnerships to fast-track the development and manufacture of Lenacapavir, aiming to broaden their global market footprint and enhance accessibility to treatments. Lenacapavir, a pioneering HIV-1 capsid inhibitor, targets various stages of the HIV lifecycle and performs well in conjunction with other antiretrovirals, making it a formidable choice for patients with restricted treatment options. For example, in August 2023, Dr. Reddy's Laboratories and Hetero, two Indian pharmaceutical companies, entered into a partnership with Gilead Sciences Inc., a US-based biopharmaceutical company. The goal of this partnership is to produce and distribute lenacapavir in 120 predominantly low to lower-middle income countries (LMICs), thereby increasing access to this cutting-edge treatment, especially for patients with multi-drug-resistant HIV who have undergone extensive previous treatments.
Who Are the Key Players in the HIV Drugs Market?
Major companies operating in the HIV drugs market include:
• Gilead Sciences Inc.
• Johnson & Johnson
• Merck & Co. Inc.
• Boehringer Ingelheim International GmbH
• Cipla
• Aurobindo Pharma
• AbbVie
• Emcure Pharmaceuticals
• Micro Labs Limited
• Northeast Pharmaceutical Group Co. Ltd
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd
• Strides Arcolab Limited
• Hetero Labs Limited
• Shanghai Desano Bio-pharmaceutical Co.
• Anhui Biochem Biopharmaceutical Co. Ltd.
• China's National Health Commission (NHC)
• Shanghai Xinxing Medicine Co. Ltd.
• China Meheco Xinxing Pharma Co. Ltd.
• CytoDyn Inc.
• Janssen Pharmaceutical
• Bavarian Nordic
• Roche Laboratories
• Pharmstandard
• Pharmasyntez
• R-Pharm
• Alium
• ChemRar Group
• Gritstone Oncology
• Enzolytics Inc.
• BioClonetics Immunotherapeutics Inc.
• Dewpoint Therapeutics
• Lyndra Therapeutics
• Mylan N.V.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG
• Teva Canada
• ViiV Healthcare Canada
• GSK
• Abbott Laboratories
• Aspen Pharmacare Limited
• Pharmacare Ltd.
What Is The Most Dominant Region In The HIV Drugs Market?
North America was the largest region in the HIV drugs market share in 2024. Middle East is expected to be the largest growing region in the global HIV drug market during the forecast period. The regions covered in the HIV drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
